Acquired osimertinib resistance in NSCLC cells is frequently associated with MET gene amplification and acquisition of the secondary EGFR C797S mutation.11,56 The present results lend credence to those observations by demonstrating that the MUC1-C-dependent inflammatory response to osimertinib resistance is activated in patient-derived (i) MGH170 cells with MET gene amplification, and (ii) MGH121/EGFR(T790M/C797S) cells. Here, MET is linked to non-small cell lung carcinoma.